SCHEMBL10325671

SCHEMBL10325671

CCCCC(=O)OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O

nearest known ligand 0.51

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ SLC2A1 P11166 1/20 0.51
▸ TLR4 O00206 1/20 0.49
▸ PTGS1 P23219 2/20 0.41
▸ PTGS2 P35354 2/20 0.41
▸ PRKD3 O94806 1/20 0.40
▸ PRKCG P05129 1/20 0.40
▸ PRKCB P05771 1/20 0.40
▸ PRKCA P17252 1/20 0.40
▸ PRKCH P24723 1/20 0.40
▸ PRKCI P41743 1/20 0.40
▸ PRKCE Q02156 1/20 0.40
▸ PRKCQ Q04759 1/20 0.40
▸ PRKCZ Q05513 1/20 0.40
▸ PRKCD Q05655 1/20 0.40
▸ PRKD1 Q15139 1/20 0.40
▸ AKT1 P31749 2/20 0.40
▸ DGKA P23743 1/20 0.40
▸ VEGFA P15692 2/20 0.39
▸ SELP P16109 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13561242 1.00 SLC2A1 (0.51) SLC2A1TLR4PTGS1PTGS2PRKD3
SCHEMBL10325673 1.00 SLC2A1 (0.51) SLC2A1TLR4PTGS1PTGS2PRKD3
SCHEMBL17318218 0.98 SLC2A1 (0.49) SLC2A1TLR4PTGS1PTGS2PRKD3
SCHEMBL9228629 0.95 TLR4 (0.51) SLC2A1TLR4PTGS1PTGS2AKT1
SCHEMBL17866084 0.95 TLR4 (0.51) SLC2A1TLR4PTGS1PTGS2AKT1
SCHEMBL9231092 0.94 TLR4 (0.53) SLC2A1TLR4PTGS1PTGS2AKT1
SCHEMBL12427213 0.94 TLR4 (0.53) SLC2A1TLR4PTGS1PTGS2AKT1
SCHEMBL8506716 0.94 TLR4 (0.53) SLC2A1TLR4PTGS1PTGS2AKT1
SCHEMBL9230804 0.94 TLR4 (0.53) SLC2A1TLR4PTGS1PTGS2AKT1
SCHEMBL6286986 0.94 TLR4 (0.53) SLC2A1TLR4PTGS1PTGS2AKT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230130134-A1 METHOD OF TREATING VIRAL INFECTIONS WITH HEXOSE TYPE MONOSACCHARIDES AND ANALOGS THEREOF BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2023-04-27 — — US disclosed
EP-4121060-A1 METHOD OF TREATING VIRAL INFECTIONS WITH HEXOSE TYPE MONOSACCHARIDES AND ANALOGS THEREOF Board of Regents, The University of Texas System (US) 2023-01-25 — — EP disclosed
WO-2021188586-A1 METHOD OF TREATING VIRAL INFECTIONS WITH HEXOSE TYPE MONOSACCHARIDES AND ANALOGS THEREOF BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2021-09-23 — — WO disclosed
EP-2663314-A2 MONOSACCHARIDE-BASED COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE AND INFLAMMATORY DERMATOLOGICAL DISEASES The University of Texas M.D. Anderson Cancer (US) 2013-11-20 — — EP disclosed
US-20120276108-A1 MONOSACCHARIDE-BASED COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE AND INFLAMMATORY DERMATOLOGICAL DISEASES INTERTECH BIO (US) 2012-11-01 — — US disclosed
WO-2012097052-A2 MONOSACCHARIDE-BASED COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE AND INFLAMMATORY DERMATOLOGICAL DISEASES INTERTECH BIO, LLC (US) 2012-07-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230130134-A1 METHOD OF TREATING VIRAL INFECTIONS WITH HEXOSE TYPE MONOSACCHARIDES AND ANALOGS THEREOF G6PD, FBP1, ALDOA SLC2A1 9/4885TLR4 658/4885PTGS1 1790/4885
US-20120276108-A1 MONOSACCHARIDE-BASED COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE AND INFLAMMATORY DERMATOLOGICAL DISEASES IGF1R, IRS1, IGFBP1 SLC2A1 21/4885TLR4 454/4885PTGS1 1198/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback